Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First-Line or Second-Line Therapy
- Determine the clinical response to paclitaxel in patients with ovarian stromal cancer.
- Determine toxicity of this drug in these patients.
- Determine the value of inhibin for predicting response in these patients when treated
with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified according to prior treatment
(yes vs no).
Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in
the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, then every 6 months for three years, and
then annually thereafter.
PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Frequency of complete clinical response
Linda Van Le, MD
UNC Lineberger Comprehensive Cancer Center
|CCOP - Christiana Care Health Services||Wilmington, Delaware 19899|
|George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus||New Britain, Connecticut 06050|
|Bronson Methodist Hospital||Kalamazoo, Michigan 49007|
|West Michigan Cancer Center||Kalamazoo, Michigan 49007-3731|
|Borgess Medical Center||Kalamazooaa, Michigan 49001|
|Aultman Cancer Center at Aultman Hospital||Canton, Ohio 44710-1799|
|MetroHealth Cancer Care Center at MetroHealth Medical Center||Cleveland, Ohio 44109|
|Rush University Medical Center||Chicago, Illinois 60612-3824|
|Holden Comprehensive Cancer Center at University of Iowa||Iowa City, Iowa 52242-1002|
|Cleveland Clinic Taussig Cancer Center||Cleveland, Ohio 44195|
|Blumenthal Cancer Center at Carolinas Medical Center||Charlotte, North Carolina 28232-2861|
|SUNY Downstate Medical Center||Brooklyn, New York 11203|
|Riverside Methodist Hospital Cancer Care||Columbus, Ohio 43214|
|Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center||Savannah, Georgia 31403-3089|
|Lucille P. Markey Cancer Center at University of Kentucky||Lexington, Kentucky 40536-0093|
|University of Mississippi Cancer Clinic||Jackson, Mississippi 39216-4505|
|Oklahoma University Cancer Institute||Oklahoma City, Oklahoma 73104|
|University of Virginia Cancer Center||Charlottesville, Virginia 22908|
|Todd Cancer Institute at Long Beach Memorial Medical Center||Long Beach, California 90801|
|Cleveland Clinic Cancer Center at Fairview Hospital||Cleveland, Ohio 44111|
|Hillcrest Cancer Center at Hillcrest Hospital||Mayfield Heights, Ohio 44124|
|Cancer Care Associates - Saint Francis Campus||Tulsa, Oklahoma 74136-1929|
|Rosenfeld Cancer Center at Abington Memorial Hospital||Abington, Pennsylvania 19001|
|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest||Allentown, Pennsylvania 18105|
|Cancer Institute of New Jersey at Cooper - Voorhees||Voorhees, New Jersey 08043|
|Palo Alto Medical Foundation||Palo Alto, California 94301|
|UAB Comprehensive Cancer Center||Birmingham, Alabama 35294|
|Tunnell Cancer Center at Beebe Medical Center||Lewes, Delaware 19958|
|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center||Columbus, Ohio 43210-1240|
|Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center||Hershey, Pennsylvania 17033-0850|
|Fox Chase Cancer Center CCOP Research Base||Philadelphia, Pennsylvania 19140|
|Union Hospital of Cecil County||Elkton MD, Maryland 21921|
|Duke Cancer Institute||Durham, North Carolina 27710|
|Gynecologic Oncology||Hinsdale, Illinois 60521|
|Louisville Oncology at Norton Cancer Institute - Louisville||Louisville, Kentucky 40202|
|Women's Cancer Center - La Canada||Las Vegas, Nevada 89169|
|South Carolina Oncology Associates, PA||Columbia, South Carolina 29210|